Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative Serplulimab with SOX in Locally Advanced Gastric or GEJ Adenocarcinoma
NCT07699939Phase 2Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Jul 2026
- Primary completion
- Nov 2028
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma comparing SOX+HLX10 with SOX+Placebo (2 arms). Primary endpoint: Pathological complete response rate. Started Jul 2026; status: recruiting.
02
Drugs
serplulimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07699939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07699939.